Loading provider…
Loading provider…
Neurology Physician in Pittsburgh, PA
NPI: 1093717092Primary Practice Location
ALLEGHENY GENERAL HOSPITAL
320 E North Ave, Pittsburgh, PA
Primary Employer
Ahn Neurology
ahn.org
HQ Phone
Get MD Thomas's Phone NumberMobile
Get MD Thomas's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
West Virginia University School Of Medicine
medicine.wvu.edu
Medical School
Until 1985
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 85 | 109 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 71 | 86 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 50 | 50 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 34 | 52 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 31 | 34 |
MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group
Authors: Steven Galetta, Andrew Blumenfeld
Publication Date: 2002-10
The Immunological Capacity of Thrombocytes.
Authors: Ferdous, Farzana, Scott, Thomas
Journal: Int J Mol Sci
Publication Date: 2023-08-18
Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale
Authors: Thomas F. Scott, Paul Nussbaum, Harry McConnell, Paul Brill
Publication Date: 1995-12
Lead Sponsor: Genzyme, a Sanofi Company
Collaborators: Bayer
Intervention / Treatment: BIOLOGICAL: Interferon beta-1a, BIOLOGICAL: Alemtuzumab
Lead Sponsor: Genzyme, a Sanofi Company
Intervention / Treatment: DRUG: alemtuzumab GZ402673
Lead Sponsor: Genzyme, a Sanofi Company
Collaborators: Bayer
Intervention / Treatment: BIOLOGICAL: alemtuzumab